Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancer
Emily Reisenbichler, Gang Han, Andrew M. Bellizzi, Veerle Bossuyt, Jane Brock, Kimberly Cole, Oluwole Fadare, Omar Hameed, Krisztina Hanley, Beth Harrison, M. Gabriela Kuba, Amy Ly, Dylan V. Miller, Mirna Podoll, Anja C. Roden, Kamaljeet Singh, Mary Ann Sanders, Shi Wei, Hannah Y. Wen, Vasiliki Pelekanou, Vesal Yaghoobi, Fahad Shabbir Ahmed, Lajos Pusztai, David L. Rimm
Topics & Concepts
ConcordanceMedicineAtezolizumabIntraclass correlationReproducibilityBreast cancerPathologyTriple-negative breast cancerInternal medicineCancerStatisticsPembrolizumabMathematicsPsychometricsClinical psychologyImmunotherapyCancer Immunotherapy and BiomarkersCancer Genomics and DiagnosticsCAR-T cell therapy research